InMed Pharmaceuticals, Inc. (IN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

InMed Pharmaceuticals, Inc.

Plus Therapeutics, Inc.

180 Life Sciences Corp.

Avalo Therapeutics, Inc.

ABVC BioPharma, Inc.

Adial Pharmaceuticals, Inc.

Palisade Bio, Inc.

Dermata Therapeutics, Inc.

Panbela Therapeutics, Inc.

Baudax Bio, Inc.

Aptorum Group Ltd.

Why is InMed Pharmaceuticals, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Flat results in Mar 25

INTEREST(9M) At USD 0.35 MM has Grown at inf%
NET PROFIT(HY) At USD -4.7 MM has Grown at -46.7%
RAW MATERIAL COST(Y) Grown by 75.6% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -68.89%, its profits have fallen by -36.7%

Falling Participation by Institutional Investors

Institutional investors have decreased their stake by -5.33% over the previous quarter and collectively hold 7.17% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Below par performance in long term as well as near term

Along with generating -68.89% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is InMed Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

InMed Pharmaceuticals, Inc.

-69.68%

5.55

113.11%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

42.71%

EBIT Growth (5y)

4.66%

EBIT to Interest (avg)

-9.96

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.61

Sales to Capital Employed (avg)

0.44

Tax Ratio

0.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.17%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.49

EV to EBIT

0.10

EV to EBITDA

0.11

EV to Capital Employed

-0.30

EV to Sales

-0.17

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-118.37%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at USD -4.7 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 4.13 times

EPS(Q)

Highest at USD -1.94

-10What is not working for the Company

INTEREST(9M)

At USD 0.35 MM has Grown at inf%

NET PROFIT(HY)

At USD -4.7 MM has Grown at -46.7%

RAW MATERIAL COST(Y)

Grown by 75.6% (YoY

CASH AND EQV(HY)

Lowest at USD 8.18 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 17.1 times

Here's what is working for InMed Pharmaceuticals, Inc.

Net Profit

Higher at USD -4.7 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 4.13 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

EPS

Highest at USD -1.94

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for InMed Pharmaceuticals, Inc.

Interest

At USD 0.35 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Profit

At USD -4.7 MM has Grown at -46.7%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 8.18 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 17.1 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 75.6% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales